Kite and Vitruvian Developing Platform to Safely Deliver T-cell Therapies at Commercial Scale

Kite and Vitruvian Developing Platform to Safely Deliver T-cell Therapies at Commercial Scale

Kite Pharma and Vitruvian Networks announced a strategic collaboration to create a software solution that will help to support commercial availability of T-cell therapies.

The companies will jointly design and develop a platform for treatment centers, doctors, and patients, enabling commercial-scale ordering, monitoring, and delivery of autologous cell therapies that have been approved by the U.S. Food and Drug Administration (FDA). These include Kite’s KTE-C19, an investigational therapy in which a patient’s T-cells are engineered to express a chimeric antigen receptor (CAR) to target CD19, a protein found at the cell surface of B-cell lymphomas and leukemias.

“We are honored to work with Kite to accelerate the design and development of Vitruvian Network’s cell and gene therapy software and data analytics platform,” said Amy DuRoss, chief executive officer of Vitruvian Networks. “Companies like Kite … require a cloud-based, design-led solution to ensure they have a safe, cost-effective, and easy-to-use platform to serve a growing number of patients.”

This partnership brings together Kite’s resources in engineered T-cell therapy, and Vitruvian cloud-based software and data analytic expertise in the commercialization and delivery of cell and gene therapies.

“Kite’s technology and services, which will be known as Kite Konnect, will directly shape the overall experience of patients, physicians, and treatment centers as engineered T-cell therapies potentially become available commercially,” Tim Moore, executive vice president of Technical Operations for Kite, said in a press release. “We are committed to advanced solutions that improve speed and customer satisfaction, streamline logistics and ensure excellence for chain of identity and custody which is essential for safety and quality.”

In related news

The Leukemia & Lymphoma Society (LLS) announced last month that it will invest $40.3 million in new efforts to advance promising blood cancer research at leading scientific and medical centers worldwide.

The investment adds 75 new research grants to the LLS portfolio of 300 supported projects, and will fund a diverse selection of work to find better treatments and, potentially, cures for leukemia, lymphoma, myeloma, and other blood cancers.

 

Leave a Comment

Your email address will not be published. Required fields are marked *